Innovative Therapies Centers of Excellence Act of 2025
Summary
HR2623 mandates the VA to establish five innovative therapies centers focused on advanced treatments including psychedelics. The bill is in early committee stage with 27 cosponsors and no appropriated funding yet. The tickers CMPS, GHRS, ATAI, and DRUG have rallied significantly over 30 days (17% to 52%) on the Executive Order and legislative signal, but remain well below 52-week highs.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2623 is a policy authorization with zero allocated funding — the market is pricing in future appropriations that do not yet exist.
- 2.All four psychedelic tickers have rallied 17-52% in 30 days but have 7-day declines of 0.2-12.4%, indicating profit-taking after the Executive Order pop.
- 3.The VA is the ideal first customer for psychedelic therapies due to the high veteran PTSD/depression prevalence, but commercialization is 2-4 years away.
- 4.Companion bill S4031 increases passage probability, but the authorization-appropriation gap remains the critical risk factor.
Market Implications
The four pure-play psychedelic developers (CMPS $8.39, GHRS $19.27, ATAI $4.17, DRUG $88.97) have already priced in significant legislative optimism with 30-day gains of 17-52%. The 7-day pullback (CMPS -12.4%, ATAI -9.9%) suggests the market is repricing the probability and timeline of actual appropriations. These stocks remain highly speculative — they are all below their 52-week highs (CMPS: 82% of high, GHRS: 78%, ATAI: 62%, DRUG: 72%) and face binary risk from the appropriations process. Investors should monitor the House VA Committee markup schedule and any FY2027 VA appropriations language. The structural bull case is intact — the VA is the ideal early adopter — but near-term momentum has stalled as the legislative reality (zero funding, early stage) sets in.
Full Analysis
HR2623, the 'Innovative Therapies Centers of Excellence Act of 2025,' was introduced in the House on April 3, 2025, by Rep. Correa (D-CA) and referred to the House Veterans' Affairs Committee. The bill requires the VA to designate at least five medical facilities as innovative therapies centers to research and deliver advanced treatments, explicitly including psychedelic-based therapies for conditions like PTSD and depression. A companion bill (S4031) has been introduced in the Senate, and an Executive Order has separately directed acceleration of psychedelic treatment reviews.
Crucially, the bill authorizes the establishment of these centers but explicitly states operations are 'subject to the availability of appropriations.' This is an authorization bill — it sets policy direction and creates a legal framework, but allocates zero dollars. Actual funding requires a separate appropriations bill. The bill has 27 cosponsors (bipartisan: Correa, Bergman, Crenshaw, Khanna, Luttrell) but remains in early committee stage with only four actions to date.
The psychedelic therapy sector has four publicly traded pure-plays: CMPS ($8.39), GHRS ($19.27), ATAI ($4.17), and DRUG ($88.97). All four have rallied sharply over the past 30 days (CMPS +51.7%, GHRS +37%, ATAI +17.8%, DRUG +21.9%) following the Executive Order announcement. However, the 7-day trend is negative (CMPS -12.4%, GHRS -4.9%, ATAI -9.9%, DRUG -0.2%), suggesting the initial Executive Order pop is fading as investors recognize the authorization-appropriation gap.
The structural winners remain the pure-play psychedelic developers because the VA represents the single largest concentrated patient population for PTSD/depression (over 1 million veterans diagnosed). Unlike the commercial insurance path (requiring lengthy reimbursement approvals), a VA center of excellence can directly procure and administer therapies. However, the legislative timeline is lengthy: the bill must pass committee, pass the House, pass the Senate (companion S4031 helps), and then secure an appropriations rider. This is a multi-year catalyst, not an imminent revenue event.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Bill mandates the VA to designate at least five medical facilities as 'innovative therapies centers of excellence' to research and deliver advanced treatments, including psychedelic-based therapies, subject to future appropriations. An Executive Order accelerating psychedelic treatments provides policy tailwind.
Who must act
Secretary of Veterans Affairs, under the Under Secretary for Health, must designate facilities and establish centers upon appropriation.
What happens
Creates a federal procurement pathway for psychedelic drug development contracts and clinical trial services targeting PTSD and depression in the veteran population (the single largest eligible cohort for such treatments).
Stock impact
CMPS is the leading pure-play developer of psilocybin therapy (COMP360), currently in Phase 3 for treatment-resistant depression. VA adoption would open a direct government procurement channel for its therapy, drastically shortening commercial adoption timelines and reducing dependence on private insurance/reimbursement.
What the bill does
Same as above — bill mandates VA innovation centers that integrate psychedelic therapies; Executive Order accelerates regulatory pathway.
Who must act
Secretary of Veterans Affairs
What happens
Creates federal demand signal for mecamylamine-based therapies (GHRS's lead candidate, GH001) for treatment-resistant depression, with VA as a first-mover adopter rather than waiting for commercial insurance coverage.
Stock impact
GHRS is developing intranasal mecamylamine for psychiatric disorders. VA centers of excellence would provide a clinical deployment venue for its lead candidate, reducing time-to-revenue and providing federal reimbursement clarity.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Mental Health Research Accelerator Act of 2025
Freedom to Heal Act of 2025
Freedom to Heal Act of 2025
Veterans Health Administration Novel Therapeutics Preparedness Act
SUPPORT for Patients and Communities Reauthorization Act of 2025
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
PANTEXAS DETERRENCE, LLC: $3.5B Department of Energy Contract
FISHER SAND & GRAVEL CO: $2.8B Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
National Security Presidential Memorandum/NSPM-12
This memorandum rescinds previous national security directives and re-establishes the Committee on National Security Systems (CNSS) to enforce baseline cybersecurity standards across all National Security Systems (NSS) operated by the Department of War, Intelligence Community, and Federal Civilian Executive Branch agencies. It creates binding directives and complementary standards that must meet or exceed NIST guidelines, empowers the NSA Director as the National Manager to issue emergency directives and cryptography requirements, and holds agency heads accountable through government-wide oversight.
National Security Presidential Memorandum/NSPM-11
This memorandum directs the national security enterprise (including the Department of War, intelligence agencies, and others) to accelerate the adoption, adaptation, and assurance of AI technologies for military and intelligence missions. It mandates updates to DOD Directive 3000.09 on autonomous weapons within 90 days, requires termination of contracts with companies that repeatedly violate policy (e.g., by enabling adversary control or embedding bias), and emphasizes supply chain resilience and multi-vendor sourcing to avoid single-vendor dependencies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.